Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
BACKGROUND
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) form a spectrum of a rare and life-threatening cutaneous drug reaction. SJS/TEN in pregnancy poses largely unknown risk factors and outcomes for both the mother and foetus compared to the general population.


METHODS
We conducted a study of consecutive pregnant women admitted to single tertiary referral centre in South Africa with SJS/TEN over a 3 year period. They were all managed by the same medical team using the same protocols. We evaluated their underlying illnesses, offending drugs and the course of pregnancy and outcomes to determine factors influencing maternal and foetal outcomes.


RESULTS
We identified twenty-two women who developed SJS/TEN while pregnant, all of them HIV-infected. Their median age was 29 years. The majority 16/22 (73%) had SJS, the milder variant of the disease affecting < 10% body surface area. Nevirapine was the offending drug in 21/22 (95%) cases. All 22 of the mothers survived with 3/22 (14%) developing postpartum sepsis. Pregnancy outcomes were known in 18/22 women and 9/18 (50%) babies were delivered by caesarean section. There were 2 foetal deaths at 21 and 31 weeks respectively and both were associated with post-partum sepsis. Postnatal complications occurred in 5 cases, 3 involving the respiratory system and the other two being low birth weight deliveries. Eight placentae and one foetus were sent for histology and none showed macroscopic or microscopic features of SJS/TEN. On follow-up, only 12/20 children were tested for HIV at 6 weeks post-delivery and none of them were HIV-infected. All had received prophylactic ARVs including nevirapine.


CONCLUSIONS
TEN, the severe form of the disease, was associated with poorer foetal outcomes. SJS/TEN-associated mortality is not increased in HIV-infected pregnant women. Maternal SJS/TEN does not seem to commonly manifest in the foetus.
Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Lauren
L
Knight
Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Gail
G
Todd
Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Rudzani
R
Muloiwa
Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa.
Mushi
M
Matjila
Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Rannakoe J
RJ
Lehloenya
D019380:Anti-HIV Agents / Q000627:therapeutic use; D005260:Female; D005333:Fetus; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D019829:Nevirapine / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000401:mortality
D019380:Anti-HIV Agents; D019829:Nevirapine